 |
|
|
|
 |
A Phase II Study of Bevacizumab for Recurrent Malignant Stromal Tumors of the Ovary
[Protocol 09-062]
- Full Title :
- A PHASE II TRIAL OF BEVACIZUMAB (RHUMAB VEGF) FOR RECURRENT SEX CORD-STROMAL TUMORS OF THE OVARY NCI-SUPPLIED AGENT: BEVACIZUMAB (NSC #704186) (GOG-0251)
- Purpose :
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab (Avastin®) in women with recurrent malignant stromal tumors of the ovary. Bevacizumab is approved for treating advanced colorectal, breast, and lung cancers as well as gliomas, and it is being assessed for its value in treating other types of cancer.
Bevacizumab works by blocking vascular endothelial growth factor (VEGF), a protein that promotes the growth of tumor cells and blood vessels in and around tumors.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of a recurrent ovarian stromal
tumor (such as granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor [androblastoma], steroid [lipid] cell tumor, gynandroblastoma,
unclassified sex cord-stromal tumor, or sex cord tumor with annular tubules).
- Patients may not have had prior therapy with bevacizumab or other VEGF inhibitors.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Mario Leitao at 212-639-3987.
|
|
|
|
|
